- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00915057
Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972.
An Open Study to Investigate the Effects of Chronic Viral Hepatitis B or C on the Pharmacokinetics of Cholyl-lysyl-fluorescein (NRL972) Before, During and After Standard Treatment.
연구 개요
연구 유형
등록 (예상)
단계
- 2 단계
연락처 및 위치
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Chronic viral hepatitis B
- Adult, male or female, age ≥ 18 years and < 65 years
- Body weight (BW) : 45 - 110 kg
- Body mass index (BMI) : 18 - 30 kg.m-2
- HBV Serology: HBsAg+ for ≥ 6 months (at the time of application for treatment)
- Serum ALT ≥ 1.5 times ULN ≥ 6 months (at the time of application for treatment)
- Positive liver biopsy within 24 months before screening visit
- Positive biopsy with signs of active disease (any level of activity by Knodell, METAVIR or ISHAK)
- HBV DNA counts determined by quantitative PCR: ≥ 20,000 IU/mL ALT < 10 times ULN
- HIV-Ab negative
- Non-cirrhotic liver disease (on histology within 24 months before screening visit)
- Not having been treated for chronic viral hepatitis previously ("de novo" i.e. "naïve")
- Eligible for treatment of chronic viral hepatitis in accordance with the national consensus guidelines pertinent to the country and site of conduct of the trial
- Willing and able to provide informed consent
Chronic viral hepatitis C
- Adult, male or female, age ≥ 18 years and < 65 years
- Body weight (BW) : 45 - 110 kg
- Body mass index (BMI) : 18 - 30 kg.m-2
- HCV-Ab+ for ≥ 6 months (at the time of application for treatment)
- HCV RNA counts > 10,000 U/L by quantitative PCR assay within the last 6 months (at the time of application for treatment)
- Positive liver biopsy within 24 months before application for treatment
- Positive biopsy with signs of fibrotic disease (levels of fibrosis METAVIR ≥ F1 or ISHAK ≥ F2)
- ALT < 10 times ULN
- HIV-Ab negative
- Non-cirrhotic liver disease (on histology within 24 months before screening visit)
- Not having been treated for chronic viral hepatitis previously ("de novo" i.e. "naïve")
- Eligible for treatment of chronic viral hepatitis in accordance with the national consensus guidelines pertinent to the country and site of conduct of the trial
- Willing and able to provide informed consent
Chronic viral hepatitis C plus chronic viral hepatitis B
- Patients with combined CHB and CHC will be managed (in terms of eligibility and standard treatment in accordance with the hepatitis type with predominant viral replication.
Exclusion Criteria:
Trial specific criteria: CHB, CHC & CHB+CHC
- Previous participation in the trial
- Participation in any other clinical trial within 30 days of entry to this protocol
- Treatment with any investigational drug within 30 days of entry to this protocol
- Non-response to previous treatment for chronic viral hepatitis
- Relapse after previous treatment for chronic viral hepatitis
- Any other known cause of liver disease other than chronic viral hepatitis B and/or C, including but not limited to hepatitis D, haemochromatosis, alpha1-antitrypsin deficiency, Wilson's disease, autoimmune hepatitis, drug-related liver disease
- Evidence of advanced liver disease, such as history or presence of ascites, bleeding varices, encephalopathy
- Patients with organ transplants
- Hypersensitivity to prospective standard treatment
- Any relevant co-morbidity, for instance, but not limited to:
- Limiting uncompensated psychiatric condition (e.g. severe depression, or a history of severe psychiatric disorder)
- CNS trauma or seizure disorder requiring medication
- Significant cardiovascular dysfunction within the past 6 months (e.g. angina, congestive cardiac failure, recent myocardial infarction, severe hypertension or significant arrhythmia)
- Patients with an ECG showing clinically significant abnormalities
- Poorly controlled diabetes mellitus
- Patients on haemodialysis
- Daily use of > 40 g alcohol
- Positive alcohol test at SCR-visit
- Evidence or suspicion of social drug abuse
- Positive drug test at SCR-visit
- Use of prohibited medication
- Suspicion or evidence that the subject is not trustworthy and reliable
- Suspicion or evidence that the subject is not able to make a free consent or to under-stand the information in this regard
Criteria specifically related to the standard treatment of chronic viral hepatitis
- Relevant clinical laboratory test abnormalities, for instance, but not limited to:
Haemoglobin (Hgb) <11 g dL-1 for women and <13 g dL-1 for men
White Blood Cell count (WBC) < 3,000 10 exp9/mL
Granulocyte count < 1,500 10 exp9/mL
Lymphocyte count < 500 10 exp9/mL
Platelets < 75,000 10 exp9/mL
Prothrombin time - INR > 1.4
Bilirubin > 25 micromol/L (except in functional hyperbilirubinaemia)
Albumin < 35 g/L
Serum creatinine > 133 micromol/L
Fasting blood glucose > 7.4 mmol/L for non-diabetic patients
HbA1c > 7% for diabetic patients
Positive auto-immune antibodies
TSH outside the normal range (for patients intended for interferon)
- Relevant co-morbidity, for instance, but not limited to:
Limiting uncompensated chronic pulmonary disease (e.g. chronic obstructive pulmonary disease)
Any medical condition requiring, or likely to require during the course of the study, chronic systemic administration of steroids
Gout - (for patients intended for interferon)
Immunologically mediated disease (e.g. inflammatory bowel disease, Crohn's disease, ulcerative colitis, rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune haemolytic anaemia, scleroderma, severe psoriasis, cryoglobulinaemia with vasculitis) - (for patients intended for interferon)
Patients with clinically significant retinal abnormalities - (for patients intended for interferon)
All females
- Positive pregnancy test
- Lactating
- Not using medically appropriate contraception and/or not willing to maintain such contraception during the treatment of chronic viral hepatitis and up to 6 months thereafter
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 특수 증상
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: NRL972
Single 2mg intravenous dose of NRL972, administered on up to seven occasions
|
Single dose of NRL972 administered at baseline, at 3-monthly intervals during treatment for up to 12 months (or the end of treatment) and at 3 and 6 months after the end of treatment.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Pharmacokinetics of NRL972
기간: Up to one hour post-dosing
|
Up to one hour post-dosing
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- NRL972-09/2008 (CHBC)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
NRL972에 대한 임상 시험
-
Cairo UniversityAhmed Elgazzar Hospital완전한